Sequential vs. prolonged 14-day triple therapy for Helicobacter pylori eradication: The meta-analysis may be influenced by 'geographical weighting'

International Journal of Clinical Practice

Volumn 69, Issue 10, 2015, Pages 1112-1120

  Losurdo, G ^a   Leandro, G ^b   Principi, M ^a   Giorgio, F ^a   Montenegro, L ^a   Sorrentino, C ^a   Ierardi, E ^a   Di Leo, A ^a  

^a UNIVERSITY OF BARI   (Italy)

^b NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; METRONIDAZOLE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CLEARANCE; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; DRUG EFFICACY; GENOTYPE; HELICOBACTER INFECTION; HUMAN; META ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; RISK REDUCTION; SEQUENTIAL THERAPY; STANDARD; TRIPLE THERAPY PROLONGATION; DRUG EFFECTS; HEALTH; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; INCIDENCE; ISOLATION AND PURIFICATION; MICROBIOLOGY; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; GLOBAL HEALTH; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INCIDENCE; TREATMENT OUTCOME;

EID: 84942821849     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12687     Document Type: Article

References (48)

1. Calvet X, Ramírez Lázaro MJ, Lehours P, Mégraud F,. Diagnosis and epidemiology of Helicobacter pylori infection. Helicobacter 2013; 18 (Suppl. 1): 5-11.
2. Ierardi E, Goni E, Losurdo G, Di Mario F,. Helicobacter pylori and nonmalignant diseases. Helicobacter 2014; 19 (Suppl 1): 27-31.
3. Zullo A, Hassan C, Cristofari F, et al., Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol 2010; 8: 105-10.
4. Roubaud Baudron C, Franceschi F, Salles N, Gasbarrini A,. Extragastric diseases and Helicobacter pylori. Helicobacter 2013; 18 (Suppl. 1): 44-51.
5. De Francesco V, Giorgio F, Hassan C, et al., Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010; 19: 409-14.
6. Giorgio F, Principi M, De Francesco V, et al., Primary clarithromycin resistance to Helicobacter pylori: is this the main reason for triple therapy failure? World J Gastrointest Pathophysiol 2013; 4: 43-6.
7. De Francesco V, Margiotta M, Zullo A, et al., Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy. J Antimicrob Chemother 2007; 59: 783-5.
8. Zullo A, Vaira D, Vakil N, et al., High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003; 17: 719-26.
9. De Francesco V, Ierardi E, Hassan C, Zullo A,. Helicobacter pylori therapy: present and future. World J Gastrointest Pharmacol Ther 2012; 3: 68-73.
10. De Francesco V, Margiotta M, Zullo A, et al., Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 2006; 144: 94-100.
11. De Francesco V, Zullo A, Ierardi E, et al., The A2143G point mutation of clarithromycin resistance affects Helicobacter pylori eradication. J Clin Gastroenterol 2009; 43: 386.
12. De Francesco V, Zullo A, Ierardi E, Vaira D,. Minimal inhibitory concentration (MIC) values and different point mutations in the 23S rRNA gene for clarithromycin resistance in Helicobacter pylori. Dig Liver Dis 2009; 41: 610-1.
13. Malfertheiner P, Megraud F, O'Morain CA, et al., Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-64.
14. Gatta L, Vakil N, Vaira D, Scarpignato C,. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013; 347: f4587.
15. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D,. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009; 104: 3069-79.
16. Ierardi E, Giorgio F, Losurdo G, Di Leo A, Principi M,. How antibiotic resistances could change Helicobacter pylori treatment: a matter of geography? World J Gastroenterol 2013; 19: 8168-80.
17. Liberati A, Altman DG, Tetzlaff J, et al., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6: e1000100.
18. Iwańczak F, Iwańczak B,. Treatment of Helicobacter pylori infection in the aspect of increasing antibiotic resistance. Adv Clin Exp Med 2012; 21: 671-80.
19. Leandro G,. Meta-Analysis in Medical Research. The Handbook for the Understanding and Practice of Meta-Analysis. Malden, MA, USA: Blackwell Publishing, Inc., 2005.
20. Greenberg ER, Anderson GL, Morgan DR, et al., 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011; 378: 507-14.
21. Baysoy G, Saltik Temizel IN, Uslu N, et al., Ornidazole-based sequential therapy is not effective in Helicobacter pylori eradication in children. Turk J Gastroenterol 2013; 24: 382-6.
22. Kim YS, Kim SJ, Yoon JH, et al., Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. Aliment Pharmacol Ther 2011; 34: 1098-105.
23. Liou JM, Chen CC, Chen MJ, et al., Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomized trial. Lancet 2012; 6736: 61579-87.
24. Nasa M, Choksey A, Phadke A, Sawant P,. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized study. Indian J Gastroenterol 2013; 32: 392-6.
25. Choi HS, Chun HJ, Park SH, et al., Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection. World J Gastroenterol 2012; 18: 2377-82.
26. Rakici H, Akdoʇan RA, Bedir R, Copur A, Yilmaz A,. Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for Helicobacter pylori infection: patient compliance and bacterial eradication rates. J Dig Dis 2014; 15: 508-13.
27. Erdur B, Ozturk Y, Gurbuz ED, Yilmaz O,. Comparison of sequential and standard therapy for Helicobacter pylori eradication in children and investigation of clarithromycin resistance. J Pediatr Gastroenterol Nutr 2012; 55: 530-3.
28. Karabiber H, Selimoglu MA, Otlu B, Yildirim O, Ozer A,. Virulence factors and antibiotic resistance in children with Helicobacter pylori gastritis. J Pediatr Gastroenterol Nutr 2014; 58: 608-12.
29. Lee JY, Kim N, Kim MS, et al., Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. Dig Dis Sci 2014; 59: 1235-43.
30. Seo JH, Jun JS, Yeom JS, et al., Changing pattern of antibiotic resistance of Helicobacter pylori in children during 20 years in Jinju, South Korea. Pediatr Int 2013; 55: 332-6.
31. Otth L, Wilson M, Fernández H, et al., Isolation of Helicobacter pylori in gastric mucosa and susceptibility to five antimicrobial drugs in Southern chile. Braz J Microbiol 2011; 42: 442-7.
32. Trespalacios AA, Otero W, Caminos JE, et al., Phenotypic and genotypic analysis of clarithromycin-resistant Helicobacter pylori from Bogotá D.C., Colombia. J Microbiol 2013; 51: 448-52.
33. Alvarez A, Moncayo JI, Santacruz JJ, et al., Antimicrobial susceptibility of Helicobacter pylori strains isolated in Colombia. Rev Med Chil 2009; 137: 1309-14.
34. Lang L, García F,. Comparison of E-test and disk diffusion assay to evaluate resistance of Helicobacter pylori isolates to amoxicillin, clarithromycin, metronidazole and tetracycline in Costa Rica. Int J Antimicrob Agents 2004; 24: 572-7.
35. Ayala G, Galván-Portillo M, Chihu L, et al., Resistance to antibiotics and characterization of Helicobacter pylori strains isolated from antrum and body from adults in Mexico. Microb Drug Resist 2011; 17: 149-55.
36. Yang YJ, Yang JC, Jeng YM, Chang MH, Ni YH,. Prevalence and rapid identification of clarithromycin-resistant Helicobacter pylori isolates in children. Pediatr Infect Dis J 2001; 20: 662-6.
37. Pandya HB, Agravat HH, Patel JS, Sodagar NR,. Emerging antimicrobial resistance pattern of Helicobacter pylori in central Gujarat. Indian J Med Microbiol 2014; 32: 408-13.
38. Tursi A, Elisei W, Giorgetti G, Picchio M, Brandimarte G,. Decreasing efficacy of the standard seven-day triple therapy containing amoxycillin and clarithromycin in curing Helicobacter pylori infection in clinical setting in Italy: a 10-year follow-up study. Panminerva Med 2014; 56: 57-61.
39. De Francesco V, Margiotta M, Zullo A, et al., Claritromycin resistance and Helicobacter pylori genotypes in Italy. J Microbiol 2006; 44: 660-4.
40. Monno R, Capolongo C, Giorgio F, et al., An overview of antibiotic phenotypic resistances to Helicobacter pylori (Hp) in Southern Italy: may tigecycline be the "drug of the future?". Helicobacter 2013; 18 (Suppl. 1): 140-1.
41. De Francesco V, Zullo A, Giorgio F, et al., Change of point mutations in Helicobacter pylori rRNA associated with clarithromycin resistance in Italy. J Med Microbiol 2014; 63 (Pt 3): 453-7.
42. Graham DY, Lee YC, Wu MS,. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014; 12: 177-86 e3
43. Lee JW, Kim N, Kim JM, et al., A comparison between 15-day sequential, 10-day sequential and proton pump inhibitor-based triple therapy for Helicobacter pylori infection in Korea. Scand J Gastroenterol 2014; 49: 917-24.
44. Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P,. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion 2013; 88: 33-45.
45. Zullo A, De Francesco V, Manes G, Scaccianoce G, Cristofari F, Hassan C,. Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice. J Gastrointestin Liver Dis 2010; 19: 131-4.
46. Zullo A, Hassan C, De Francesco V, et al., A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. Dig Liver Dis 2003; 35: 232-6.
47. Ierardi E, Giangaspero A, Losurdo G, et al., Quadruple rescue therapy after first and second line failure for Helicobacter pylori treatment: comparison between two tetracycline-based regimens. J Gastrointestin Liver Dis 2014; 23: 367-70.
48. Georgopoulos SD, Papastergiou V, Karatapanis S,. Current options for the treatment of Helicobacter pylori. Expert Opin Pharmacother 2013; 14: 211-23.